DLC2 inhibits development of glioma through regulating the expression ratio of TAp73α/TAp73β
Related Experiment Video
Updated: Feb 6, 2026

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
Published on: September 6, 2024
Chao Cheng1, Suyin Feng1, Jiantong Jiao1
1Department of Neurosurgery, Wuxi People's Hospital of Nanjing Medical University Wuxi 214023, Jiangsu, China.
Abstract:
To date, the anti-tumor mechanism of the deleted in liver cancer 2 (DLC2) in gliomas is still unclear. The study shows that TAp73α expression and TAp73α/TAp73β ratio are frequently high in gliomas and that TAp73α and TAp73β have opposite roles in regulating proliferation and apoptosis of glioma cells. Moreover, DLC2 is low-expressed in gliomas, which negatively correlates with TAp73α expression and TAp73α/TAp73β ratio. More importantly, DLC2 inhibits development of glioma by decreasing expression of TAp73α, which changes the expression ratio of TAp73α/TAp73β in glioma cells. Mechanically, DLC2 interacts directly with TAp73α and induces TAp73α ubiquitination and degradation, which is mediated through SAM domain of DLC2 and TAp73α. In detail, DLC2 with SAM domain deletion fails to interact with TAp73α and induce TAp73α ubiquitination and degradation, and SAM deletion decreased tumorigenesis-inhibition effect of DLC2. In conclusion, DLC2 inhibits glioma development by inducing TAp73α degradation and subsequent change of TAp73α/TAp73β expression ratio.
Insights
Deleted in liver cancer 2 (DLC2) inhibits glioma development by targeting TAp73α for degradation. This mechanism reduces the TAp73α/TAp73β ratio, impacting glioma cell proliferation and apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Gliomas exhibit high TAp73α expression and TAp73α/TAp73β ratios, with opposing roles in cell proliferation and apoptosis.
- Deleted in liver cancer 2 (DLC2) is downregulated in gliomas, inversely correlating with TAp73α levels and the TAp73α/TAp73β ratio.
Purpose of the Study:
- To elucidate the anti-tumor mechanism of DLC2 in glioma.
- To investigate the role of DLC2 in regulating TAp73α and TAp73β expression in glioma cells.
Main Methods:
- Analysis of TAp73α and TAp73β expression and their ratio in gliomas.
- Investigation of DLC2 expression and its correlation with TAp73α/TAp73β ratio.
- Assessment of DLC2's effect on glioma cell proliferation and apoptosis.
- Examination of DLC2-TAp73α interaction and ubiquitination via SAM domain.
Main Results:
- DLC2 inhibits glioma development by decreasing TAp73α expression, altering the TAp73α/TAp73β ratio.
- DLC2 directly interacts with TAp73α, inducing its ubiquitination and degradation, a process mediated by the SAM domain of DLC2.
- Deletion of the SAM domain in DLC2 abrogates TAp73α interaction and degradation, diminishing DLC2's tumor-suppressive effect.
Conclusions:
- DLC2 functions as a tumor suppressor in gliomas by targeting TAp73α for degradation.
- The DLC2-mediated reduction in TAp73α levels and subsequent alteration of the TAp73α/TAp73β ratio represent a key anti-glioma mechanism.
More Related Videos
Related Concept Videos
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
Regulation of Expression Occurs at Multiple Steps
Regulation of Expression at Multiple Steps
Epigenetic Regulation
Constitutive and Regulated Gene Expression
Master Transcription Regulators

